Humira Biosimilar Switch 2026: 8 FDA-Approved Alternatives Compared

Humira (adalimumab) was the world's best-selling drug for more than a decade. AbbVie's US patent fortress finally opened in 2023 when the first biosimilars entered the market. By 2026, eight distinct adalimumab biosimilars are marketed in the United States: Amjevita (Amgen), Cyltezo (Boehringer Ingelheim), Hadlima (Samsung Bioepis/Organon), Hulio (Mylan/Fujifilm), Hyrimoz (Sandoz), Simlandi (Alvotech), Yuflyma (Celltrion), and Abrilada (Pfizer). Two additional biosimilars, Yusimry (Coherus) and Idacio (Fresenius Kabi), have FDA approval but are not among the eight primarily active in the 2026 commercial market. All eight share Humira's approved indications and the same active molecule, adalimumab, a human IgG1 monoclonal antibody targeting tumor necrosis factor.

All eight actively marketed biosimilars carry the FDA interchangeable designation: Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Simlandi, Yuflyma, and Abrilada. Abrilada (Pfizer) received its interchangeable designation from the FDA on October 5, 2023. The interchangeable designation allows pharmacists in most states to substitute a biosimilar for brand Humira at the pharmacy counter without a new prescription from the prescriber. The FDA's interchangeable standard requires that the biosimilar can be expected to produce the same clinical result as the reference product in any given patient, and that switching between the reference product and the biosimilar does not increase safety or efficacy risks compared to using the reference product without switching. Patients on Medicaid typically pay $1 to $4 in copays for biosimilar adalimumab when it is on formulary. The full list of FDA-approved biologics and biosimilars is maintained in the FDA's Purple Book database at purplebooksearch.fda.gov.

Despite significant biosimilar competition, Humira's 2026 list price of $6,922 per month has not meaningfully declined. AbbVie relies on rebate arrangements with pharmacy benefit managers to maintain Humira's formulary position at some plans while biosimilar manufacturers compete on net price. From a cash-pay standpoint, the savings are dramatic: unbranded adalimumab-adbm (Cyltezo's active ingredient) is available through GoodRx at approximately $550 per carton, a 92 percent discount from Humira's list price. For patients covered by Medicare Part D, the 2026 annual out-of-pocket cap of $2,100 applies, and most 2026 Medicare Part D formularies place biosimilar adalimumab at Tier 1 or Tier 2 while excluding brand Humira or placing it at Tier 5. The Inflation Reduction Act of 2022, which established the $2,100 Part D cap, has particularly benefited high-cost biologic users who previously faced catastrophic-phase cost-sharing above $7,000 per year.

What Humira Biosimilars Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same humira biosimilars can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Medicare pays approximately $1,853 per month for a standard two-dose adalimumab regimen using J0139 (2 doses of 40mg x 40 units x $23.16/mg). Michigan price transparency data published by the Michigan Health Purchasers Coalition shows commercial payer rates at facilities in the same metropolitan area ranging from under $2,000 to over $15,800 for the identical monthly treatment cycle. The more than $11,000 spread within one metro area is not a difference in drug quality or patient safety. All FDA-approved adalimumab biosimilars use the same active molecule, carry the same approved indications, and are billed under the same J0139 code. The price variation reflects facility markup structures, not therapeutic differences.

Hospitals apply facility rates that bundle drug acquisition cost with nursing administration, pharmacy handling, storage, and system-wide overhead allocations. For a high-cost biologic like adalimumab, facility markups above the Medicare ASP can reach 4x to 8x. Academic medical centers with high commercial payer volume routinely bill adalimumab at rates that exceed the Medicare ASP by 500 percent or more. The patient's share at 20 percent coinsurance means a patient at a high-markup outpatient facility could owe more than $3,000 per monthly injection cycle compared to $370 at a facility billing near the Medicare ASP. When a biosimilar is administered but a higher-priced brand is billed, that is a billing error. Each biosimilar has its own ASP rate published in the CMS quarterly files, and claims should reflect the product actually administered.

Choosing where to receive the injection matters as much as choosing the drug. Hospital price transparency rules require most facilities to publish negotiated rates, though compliance and enforcement remain inconsistent. If you receive adalimumab in a clinical setting, ask your rheumatologist or gastroenterologist whether a lower-cost infusion suite, independent outpatient clinic, or home self-injection is clinically appropriate. Most adalimumab biosimilars are formulated for home self-injection via prefilled pen or syringe, which eliminates facility fees entirely and subjects the drug only to the pharmacy channel pricing shown in the table above.

HCPCS J-Codes: What Appears on Your Bill

Adalimumab administered in a clinical setting (doctor's office, infusion suite, hospital outpatient department) is billed under HCPCS Level II J-codes. Effective January 1, 2025, CMS deleted J0135 (injection, adalimumab, 20mg) and replaced it with J0139 (injection, adalimumab, 1mg). Both brand Humira and biosimilar adalimumab products administered in a clinical setting are billed under J0139. The unit difference matters: under J0135, a 40mg dose was billed as 2 units; under J0139, a 40mg dose is billed as 40 units. Any claim using J0135 for a date of service on or after January 1, 2025 is using an invalid code and should be corrected.

Patient Assistance Programs

AbbVie's myAbbVie Assist patient assistance program stopped accepting new Humira applicants on July 1, 2026, because of biosimilar availability. Patients who were enrolled in myAbbVie Assist for Humira before that date can complete their current eligibility term but cannot renew for Humira. For patients starting adalimumab therapy in 2026, each biosimilar manufacturer operates its own assistance program. The HUMIRA Complete savings card remains available for commercially insured patients and reduces monthly copays to $0, but federal law bars its use with Medicare, Medicaid, TRICARE, or VA benefits. Patients without commercial insurance should apply directly to the biosimilar manufacturer's patient assistance program for the specific product their provider prescribes.

Medicare Part D

Most Medicare patients receive adalimumab under Part B (provider-administered, billed with J0139), not Part D. If you self-administer biosimilar adalimumab at home and your Part D plan covers it, the 2026 annual out-of-pocket cap of $2,100 established by the Inflation Reduction Act applies. There is no specific monthly Part D cap for adalimumab (unlike insulin's $35/month cap). By 2026, most Medicare Part D formularies have placed biosimilar adalimumab products on lower tiers (Tier 1 or Tier 2) and either excluded brand Humira or placed it at Tier 5 (specialty tier). An HHS OIG analysis of 2025 Medicare Part D plan formularies found broad adoption of adalimumab biosimilars across commercial plans.

Patients approaching formulary tier assignment should check their plan's current drug list at Medicare.gov before filling a prescription, because a lower-tier biosimilar can mean hundreds of dollars less per month in cost-sharing. If your plan has assigned your prescribed adalimumab product to a higher formulary tier, you can request a formulary exception or appeal the tier assignment based on your prescriber's clinical justification. The Inflation Reduction Act also allows Medicare patients to pay up front on a monthly basis for Part D costs (smoothing), so a high monthly adalimumab bill can be spread evenly rather than hitting all at once in the deductible phase.

Common Humira Biosimilars Billing Errors

Adalimumab biosimilar switches introduce specific billing error risks beyond those seen with brand Humira. The HCPCS code change from J0135 to J0139 in January 2025, combined with multiple biosimilar products entering the market, creates multiple points of potential error on Explanations of Benefits and itemized bills:

• Stale J0135 code: Any claim for adalimumab (brand or biosimilar) with a date of service on or after January 1, 2025 using J0135 is using a deleted code. Request correction and resubmission with J0139.
• Wrong unit count for J0139: A 40mg dose = 40 units of J0139 (not 2 units). If the bill shows J0139 x 2 units, units are being billed as if J0135 units still applied. Verify: units billed times 1mg per unit must equal the total milligrams administered.
• Brand billed, biosimilar administered: Your EOB shows Humira charges but the pharmacy dispensed Hadlima, Hyrimoz, or another biosimilar. Each biosimilar has its own ASP rate; billing the brand rate when a biosimilar was dispensed is a billing error. The biosimilar's specific NDC and name should appear on the claim.
• Prior authorization mismatch after a biosimilar switch: Your plan approved Humira (or one biosimilar) but you were switched to a different biosimilar without updating the prior authorization. The new biosimilar may be denied. Always verify that your current PA reflects the specific product your pharmacy is dispensing.
• Duplicate injection billing: Two line items for the same date of service when only one dose was administered. Check that each J0139 line item corresponds to a distinct injection date and distinct dose quantity.

Frequently Asked Questions